PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma
- Resource Type
- Article
- Authors
- Brown, Fiona; Zhang, Yang; Hinterschied, Claire; Prouty, Alexander; Sloan, Shelby; Helmig-Mason, JoBeth; Chung, Ji Hyun; Vaddi, Kris; Chen-Kiang, Selina; Di Liberto, Maurizio; Alinari, Lapo; Scherle, Peggy; Lapalombella, Rosa; Paik, Jihye; Baiocchi, Robert A
- Source
- Blood; November 2019, Vol. 134 Issue: Supplement 1 p302-302, 1p
- Subject
- Language
- ISSN
- 00064971; 15280020
Zhang: Prelude Therapeutics: Employment. Vaddi:Prelude Therapeutics: Employment. Scherle:Prelude Therapeutics: Employment. Baiocchi:Prelude: Consultancy.